Clinical Development
Allogeneic iPS cell-derived retinal pigment epithelium transplantation for age-related macular degeneration
Sumitomo Pharma Co., Ltd.
Sumitomo Pharma is developing allogeneic iPS cell-derived retinal pigment epithelium with HEALIOS K.K. We aim to start a company initiated clinical study in Japan in FY2022 and launch our products in FY2025.
